Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis
Authors' conclusion
Our meta-analysis supports therapeutic benefits of liraglutide for patients with T1DM mainly for weight loss and insulin dose reduction. Newly diagnosed or C-pos patients do not appear to experience greater weight loss benefits.
Study context
- Population
- Patients with T1D; RCTs to December 2022
- Participants
- 3,377 patients24 studies
- Comparison
- GLP-1 analogues as adjunctive therapy in T1D
- Outcome
- Efficacy outcomes: HbA1c, body weight and total daily insulin (TDI)
- Follow-up
- After ≥12 weeks of GLP-1 therapy
Methodological detailsGRADE certainty assessment, subgroup analysis for newly diagnosed or C-peptide positive patients
- GRADE certainty assessment
- Subgroup analysis for newly diagnosed or C-peptide positive patients
Pooled result
As reported in the abstract
Liraglutide effect sizes (per mg dose)
| Group | HbA1c | Weight | Total daily insulin (TDI) |
|---|---|---|---|
| Liraglutide | −0.09%/mg | −2.2 kg/mg | −4.32 IU/mg |
Liraglutide
HbA1c−0.09%/mg
Weight−2.2 kg/mg
Total daily insulin (TDI)−4.32 IU/mg
Further pooled results
Subgroup: C-peptide positive patients
- Greater HbA1c decrease among C-pos patients (C-pos vs comparison as printed)
- −0.51% vs −0.28%
- Similar weight loss and TDI
Safety
Adverse outcomes
| OR (95% CI) | ||
|---|---|---|
| LiraglutideNausea; higher odds with liraglutide dose | 6.5 (5.0–8.4) | |
| LiraglutideKetosis; higher odds with liraglutide dose | 1.8 (1.1–2.8) | |
| 0.10.31310Odds ratio (log scale) |
- Adverse outcomes — Odds of severe hypoglycemia not significantly elevated
- OR 0.67; 95% CI, 0.43-1.04
- Adverse outcomes — Odds of symptomatic hypoglycemia not significantly elevated
- OR 0.89; 95% CI, 0.53-1.51
Adverse outcomes
- Exenatide: safety data were sparse
Original publication
Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab. Published 10 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →